302 related articles for article (PubMed ID: 29104248)
1. Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.
Faes S; Santoro T; Demartines N; Dormond O
Cancers (Basel); 2017 Nov; 9(11):. PubMed ID: 29104248
[TBL] [Abstract][Full Text] [Related]
2. Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment.
El Hage A; Dormond O
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802831
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Dormond-Meuwly A; Roulin D; Dufour M; Benoit M; Demartines N; Dormond O
Biochem Biophys Res Commun; 2011 Apr; 407(4):714-9. PubMed ID: 21439267
[TBL] [Abstract][Full Text] [Related]
4. Overcoming resistance to rapalogs in gliomas by combinatory therapies.
Grzmil M; Hemmings BA
Biochim Biophys Acta; 2013 Jul; 1834(7):1371-80. PubMed ID: 23395884
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
6. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
7. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Dey N; Sun Y; Carlson JH; Wu H; Lin X; Leyland-Jones B; De P
Am J Cancer Res; 2016; 6(4):714-46. PubMed ID: 27186427
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery targeting the mTOR pathway.
Martelli AM; Buontempo F; McCubrey JA
Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
[TBL] [Abstract][Full Text] [Related]
10. Tumor vasculature: the Achilles' heel of cancer?
Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.
Merk H; Zhang S; Lehr T; Müller C; Ulrich M; Bibb JA; Adams RH; Bracher F; Zahler S; Vollmar AM; Liebl J
Oncotarget; 2016 Feb; 7(5):6088-104. PubMed ID: 26755662
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.
Lamanuzzi A; Saltarella I; Desantis V; Frassanito MA; Leone P; Racanelli V; Nico B; Ribatti D; Ditonno P; Prete M; Solimando AG; Dammacco F; Vacca A; Ria R
Oncotarget; 2018 Apr; 9(29):20563-20577. PubMed ID: 29755672
[TBL] [Abstract][Full Text] [Related]
13. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
Magaway C; Kim E; Jacinto E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapy as a cancer treatment paradigm.
Dhanabal M; Jeffers M; Larochelle WJ
Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):115-30. PubMed ID: 15777219
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M
Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724
[TBL] [Abstract][Full Text] [Related]
16. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
17. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.
Singleton PA; Mambetsariev N; Lennon FE; Mathew B; Siegler JH; Moreno-Vinasco L; Salgia R; Moss J; Garcia JG
J Angiogenes Res; 2010 Feb; 2(1):5. PubMed ID: 20298531
[TBL] [Abstract][Full Text] [Related]
18. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
19. The applicability of mTOR inhibition in solid tumors.
Konings IR; Verweij J; Wiemer EA; Sleijfer S
Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
[TBL] [Abstract][Full Text] [Related]
20. Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.
Zhang X; Li XR; Zhang J
Curr Cancer Drug Targets; 2013 Feb; 13(2):175-87. PubMed ID: 23215724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
